Current Diabetes Reports

, 11:154

Gut Microbiota and the Pathogenesis of Insulin Resistance



Several reviews recently explored how the gut microbiota was able to control host energy metabolism, and thereby the development of adiposity. In this review, we focused on the state of the art that supports a link between the gut microbiota composition and activity, and the management of glycemia associated with overweight and diabetes. Several microbial-derived compounds are related to disturbances of glucose homeostasis including the gram-negative–derived lipopolysaccharides. Some nutrients with prebiotic properties, which escape the digestion in the upper part of the gut, modify the composition of the gut microbiota in favor of bacteria that could play a beneficial role on glucose homeostasis, namely by modulating the endocrine function of the gut, and by reinforcing the gut barrier. Adequate intervention studies in diabetic patients are required to assess the relevance of those experimental data for human health.


Gut microbiota Diabetes Prebiotics Inflammation Gut Lipopolysaccharides 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Cani PD, Delzenne NM: The gut microbiome as therapeutic target. Pharmacol Ther 2011. doi:10.1016/J.PHARMTHERA.2011.01.012
  2. 2.
    Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008;7:123–9.PubMedCrossRefGoogle Scholar
  3. 3.
    • Backhed F, Crawford PA. Coordinated regulation of the metabolome and lipidome at the host-microbial interface. Biochim Biophys Acta. 2010;1801:240–5. This paper reviews the collected data related to the metabolomic approach to evaluate microbial-host interactions.PubMedGoogle Scholar
  4. 4.
    Kovacs A, Ben-Jacob N, Tayem H, et al. Genotype is a stronger determinant than sex of the mouse gut microbiota. Microb Ecol. 2011;61:423–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol. 2010;26:5–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol. 2009;9:737–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004;101:15718–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice 1. Proc Natl Acad Sci USA. 2007;104:979–84.PubMedCrossRefGoogle Scholar
  9. 9.
    Diamant M, Blaak EE, de Vos WM: Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev 2010.Google Scholar
  10. 10.
    Rabot S, Membrez M, Bruneau A, et al. Germ-free C57BL/6 J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 2010;24:4948–59.PubMedCrossRefGoogle Scholar
  11. 11.
    Fleissner CK, Huebel N, Abd El-Bary MM, et al. Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br J Nutr. 2010;104:919–29.PubMedCrossRefGoogle Scholar
  12. 12.
    •• Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328:228–31. This is one of the key papers showing the transferability of the diabetic phenotype by inoculation of the gut microbiota to germ-free mice.PubMedCrossRefGoogle Scholar
  13. 13.
    Delzenne NM, Cani PD. Nutritional modulation of gut microbiota in the context of obesity and insulin resistance: Potential interest of prebiotics. Int Dairy J. 2010;20:277–80.CrossRefGoogle Scholar
  14. 14.
    Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.PubMedCrossRefGoogle Scholar
  16. 16.
    Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116:3015–25.PubMedCrossRefGoogle Scholar
  17. 17.
    •• Basu S, Haghiac M, Surace P, et al. Pregravid obesity associates with increased maternal endotoxemia and metabolic inflammation. Obesity (Silver Spring). 2011;19:476–82. This is interesting data relating the inflammation status and microbial changes upon pregnancy and fat mass development.CrossRefGoogle Scholar
  18. 18.
    Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Sun L, Yu Z, Ye X, et al. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diab Care. 2010;33:1925–32.CrossRefGoogle Scholar
  20. 20.
    Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50:2374–83.PubMedCrossRefGoogle Scholar
  21. 21.
    Amar J, Burcelin R, Ruidavets JB, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr. 2008;87:1219–23.PubMedGoogle Scholar
  22. 22.
    Ghanim H, Abuaysheh S, Sia CL, et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diab Care. 2009;32:2281–7.CrossRefGoogle Scholar
  23. 23.
    Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr. 2007;86:1286–92.PubMedGoogle Scholar
  24. 24.
    Cani PD, Possemiers S, Van de WT, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58:1091–103.PubMedCrossRefGoogle Scholar
  25. 25.
    • Muccioli GG, Naslain D, Backhed F, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010;6:392. This is a paper describing the implication of the endocannabinoid system in the intestine and in the adipose tissue in the host response toward gut microbiota.PubMedCrossRefGoogle Scholar
  26. 26.
    de La Serre CB, Ellis CL, Lee J, et al. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol. 2010;299:G440–8.CrossRefGoogle Scholar
  27. 27.
    Le PE, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation 1. J Biol Chem. 2003;278:25481–9.CrossRefGoogle Scholar
  28. 28.
    Samuel BS, Shaito A, Motoike T, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci USA. 2008;105:16767–72.PubMedCrossRefGoogle Scholar
  29. 29.
    Hong YH, Nishimura Y, Hishikawa D, et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology. 2005;146:5092–9.PubMedCrossRefGoogle Scholar
  30. 30.
    • Al-Lahham SH, Peppelenbosch MP, Roelofsen H, et al. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim Biophys Acta. 2010;1801:1175–83. This is a complete review of the state of the art concerning the metabolic regulation by propionate.PubMedGoogle Scholar
  31. 31.
    Gao Z, Yin J, Zhang J, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009;58:1509–17.PubMedCrossRefGoogle Scholar
  32. 32.
    Neyrinck AM, Delzenne NM. Potential interest of gut microbial changes induced by non-digestible carbohydrates of wheat in the management of obesity and related disorders. Curr Opin Clin Nutr Metab Care. 2010;13:722–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Ley RE, Backhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA. 2005;102:11070–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Duncan SH, Lobley GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond). 2008;32:1720–4.CrossRefGoogle Scholar
  35. 35.
    Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA. 2009;106:2365–70.PubMedCrossRefGoogle Scholar
  36. 36.
    Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009;137:1716–24.PubMedCrossRefGoogle Scholar
  37. 37.
    Murphy EF, Cotter PD, Healy S, et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut. 2010;59:1635–42.PubMedCrossRefGoogle Scholar
  38. 38.
    Kalliomaki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr. 2008;87:534–8.PubMedGoogle Scholar
  39. 39.
    Collado MC, Isolauri E, Laitinen K, Salminen S. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. 1. Am J Clin Nutr. 2008;88:894–9.PubMedGoogle Scholar
  40. 40.
    O’Mahony D, Murphy S, Boileau T, et al. Bifidobacterium animalis AHC7 protects against pathogen-induced NF-kappaB activation in vivo. BMC Immunol. 2010;11:63.PubMedCrossRefGoogle Scholar
  41. 41.
    Schwiertz A, Taras D, Schafer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obes Silver Spring. 2010;18:190–5.CrossRefGoogle Scholar
  42. 42.
    •• Luoto R, Kalliomaki M, Laitinen K, et al. Initial dietary and microbiological environments deviate in normal-weight compared to overweight children at 10 years of age. J Pediatr Gastroenterol Nutr. 2011;52:90–5. This is interesting data supporting the relevance of the changes in microbiota early in life on the occurrence of overweight and obesity.PubMedCrossRefGoogle Scholar
  43. 43.
    Luoto R, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. Br J Nutr. 2010;103:1792–9.PubMedCrossRefGoogle Scholar
  44. 44.
    •• Furet JP, Kong LC, Tap J, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010;59:3049–57. This is a key paper describing the relationship between the level of F. Prausnitzii in the fecal samples of obese humans, and the development of diabetes and inflammation.PubMedCrossRefGoogle Scholar
  45. 45.
    Santacruz A, Collado MC, Garcia-Valdes L, et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr. 2010;104:83–92.PubMedCrossRefGoogle Scholar
  46. 46.
    •• Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5:e9085. This is novel data comparing the changes in gut in the profile of bacteria in diabetic and nondiabetic patients.PubMedCrossRefGoogle Scholar
  47. 47.
    •• Wu X, Ma C, Han L, et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol. 2010;61:69–78. This is one of the rare data published in humans that report the changes in gut microbiota with a focus on bifidobacteria composition in diabetic patients.PubMedCrossRefGoogle Scholar
  48. 48.
    Zhao X, Fritsche J, Wang J, et al. Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics. 2010;6:362–74.PubMedCrossRefGoogle Scholar
  49. 49.
    Roberfroid M, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104 Suppl 2:S1–63.PubMedCrossRefGoogle Scholar
  50. 50.
    Cani PD, Knauf C, Iglesias MA, et al. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like Peptide 1 receptor. Diabetes. 2006;55:1484–90.PubMedCrossRefGoogle Scholar
  51. 51.
    Cani PD, Lecourt E, Dewulf EM, et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr. 2009;90:1236–43.PubMedCrossRefGoogle Scholar
  52. 52.
    Kaji I, Karaki SI, Tanaka R, Kuwahara A: Density distribution of free fatty acid receptor 2 (FFA2)-expressing and GLP-1-producing enteroendocrine L cells in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide. J Mol Histol 2010.Google Scholar
  53. 53.
    Tarini J, Wolever TM. The fermentable fibre inulin increases postprandial serum short-chain fatty acids and reduces free-fatty acids and ghrelin in healthy subjects. Appl Physiol Nutr Metab. 2010;35:9–16.PubMedCrossRefGoogle Scholar
  54. 54.
    Abrams SA, Griffin IJ, Hawthorne KM, Ellis KJ. Effect of prebiotic supplementation and calcium intake on body mass index. J Pediatr. 2007;151:293–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Genta S, Cabrera W, Habib N, et al. Yacon syrup: beneficial effects on obesity and insulin resistance in humans. Clin Nutr. 2009;28:182–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr. 2009;89:1751–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Luo J, Van YM, Rizkalla SW, et al. Chronic consumption of short-chain fructooligosaccharides does not affect basal hepatic glucose production or insulin resistance in type 2 diabetics. J Nutr. 2000;130:1572–7.PubMedGoogle Scholar
  58. 58.
    Giacco R, Clemente G, Luongo D, et al. Effects of short-chain fructo-oligosaccharides on glucose and lipid metabolism in mild hypercholesterolaemic individuals. Clin Nutr. 2004;23:331–40.PubMedCrossRefGoogle Scholar
  59. 59.
    Freeland KR, Wilson C, Wolever TM. Adaptation of colonic fermentation and glucagon-like peptide-1 secretion with increased wheat fibre intake for 1 year in hyperinsulinaemic human subjects. Br J Nutr. 2010;103:82–90.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Louvain Drug Research Institute, Metabolism and Nutrition Research GroupUniversité Catholique de LouvainBrusselsBelgium
  2. 2.LDRI/MNUTUCLBrusselsBelgium

Personalised recommendations